|
|
|
M Bio Technology Inc. is the innovative biotechnology company.
M Bio Technology Inc. is focusing the diagnosis, therapeutic and prevention
of Mycoplasma Infectious Diseases(MID)
Mycoplasma Infectious Diseases (MID) cause systemic vasculitis/neuritis
and to be the cause of chronic or incurable disease.
Mycoplasma infection cause not only pneumonia but vasculitis based asthma,
arthritis, nephritis, meningitis, encephalitis, arteritis, dermatitis.
Further, Mycoplasma Infectious Disease (MID)presents variegated condition,
such as autoimmune diseases, rheumatic disease and a nervous system disorders,
innflammatory diseases.
Clinicallly, it become oftenly important to determine the cause of interstitial
pneumonia and/or Stevens-Johnson syndrome, whether severe side effect of
drug or mycoplasma. including Stevens-Johnson syndrome (SJS), Kawasaki
disease, or Multiple Sclerosis (MS).
The mycoplasma vaccine and diagnostics using the synthesized glycolipid antigen are world's first platform technology.
The concept of vaccine for MID is First in Class, simplest vaccine, whose component are chemically-synthesized glycolipid-antigens.
The core technology is structural anlysis and chemical synthesis of mycoplasma
lipid-antigens. The microorganism lipid antigen analysis technology is
introduced into clinical diagnosis-treatment, and it challenges overcoming
the disease to which the lipid antigen is related.
It becomes possible to discover MID at an early stage, and to treat a cause
of a disease curatively with this medical treatment.
We are creating global network for for the precision medicine, and seeking
for partners to develop companion diagnostic, vaccine, the partner of maycoplasma
vaccine in the pharmaceutical companies and biotech industries world wide.
It is assumed to be a mission to put study results of the mycoplasma lipid antigen to practical use, and to contribute to the establishment of diagnosis-prevention-treatment method of the mycoplasma infectious disease.
|
|
|